All In Biotech

Drug Trial Radar · NCT05466877

A Study of MG-K10 in Subjects With Atopic Dermatitis

Phase II Clinical Trial of Safety, Pharmacokinetics and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Adult Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 163 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

163

Planned (sponsor's estimate)

Start

Aug 31, 2022

Primary completion

Sep 22, 2023

Study completion May 26, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the preliminary efficacy of MG-K10 in subjects with moderate to severe asthma, and provides a basis for the design and dosing regimen of phase III clinical trials.

Conditions

  • Atopic Dermatitis

Interventions

  • MG-K10Drug

    MG-K10 Humanized Monoclonal Antibody Injection

  • PlaceboDrug

    MG-K10 Humanized Monoclonal Antibody Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from baseline in EASITime frame: 16 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.